Edition:
United States

pSivida Corp (PSDV.OQ)

PSDV.OQ on NASDAQ Stock Exchange Global Market

1.10USD
16 Feb 2018
Change (% chg)

$0.01 (+0.92%)
Prev Close
$1.09
Open
$1.09
Day's High
$1.13
Day's Low
$1.08
Volume
39,088
Avg. Vol
70,263
52-wk High
$2.45
52-wk Low
$0.93

Chart for

About

pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that... (more)

Overall

Beta: 1.21
Market Cap(Mil.): $49.78
Shares Outstanding(Mil.): 45.26
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-Psivida Corp Reports Q2 Loss Per Share $0.13

* REPORTS SECOND QUARTER FY2018 RESULTS; CONTINUES TO ACHIEVE MILESTONES AND TIMELINES

Feb 07 2018

BRIEF-Psivida's Second Phase 3 Study For Durasert Three-Year Treatment For Posterior Segment Uveitis Maintains Positive Efficacy And Safety Profile At 12 Months

* PSIVIDA'S SECOND PHASE 3 STUDY FOR DURASERT™ THREE-YEAR TREATMENT FOR POSTERIOR SEGMENT UVEITIS MAINTAINS POSITIVE EFFICACY AND SAFETY PROFILE AT 12 MONTHS

Feb 07 2018

BRIEF-pSivida Submits New Drug Application For Durasert Three-Year Treatment For Posterior Segment Uveitis To The U.S. FDA

* PSIVIDA SUBMITS NEW DRUG APPLICATION (NDA) FOR DURASERT™ THREE-YEAR TREATMENT FOR POSTERIOR SEGMENT UVEITIS TO THE U.S. FDA

Jan 08 2018

BRIEF-Psivida Granted Waiver By The FDA For New Drug Application Filing Fee

* PSIVIDA GRANTED WAIVER BY THE FDA FOR NEW DRUG APPLICATION FILING FEE

Jan 04 2018

BRIEF-HSS And PSivida Report Positive Phase 1 Knee Osteoarthritis Pain Study Data

* HSS AND PSIVIDA REPORT POSITIVE PHASE 1 KNEE OSTEOARTHRITIS PAIN STUDY DATA

Dec 14 2017

BRIEF-pSivida reports Q1 loss per share of $0.15

* Q1 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Nov 07 2017

BRIEF-Nicox and pSivida enter strategic collaboration agreement

* REG-NICOX AND PSIVIDA ENTER STRATEGIC COLLABORATION AGREEMENT TO DEVELOP SUSTAINED RELEASE DRUG TO LOWER INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA

Oct 10 2017

BRIEF-Nicox and pSivida enter collaboration agreement to develop sustained release drug for glaucoma patients​

* Nicox-Co and pSivida enter strategic collaboration agreement to develop sustained release drug to lower intraocular pressure in patients with glaucoma​

Oct 10 2017

BRIEF-pSivida partners with global pharmaceuticals company to develop sustained release formulations of glaucoma drugs

* pSivida partners with global pharmaceuticals company to develop sustained release formulations of glaucoma drugs

Sep 26 2017

BRIEF-pSivida Corp reports Q4 loss per share $0.16

* pSivida Corp achieves significant milestones throughout fy 2017; reports fourth quarter and fiscal 2017 results

Sep 11 2017

Earnings vs. Estimates